NHS England and Wales Approves Teplizumab for Type 1 Diabetes Delay
The first medication capable of delaying the onset of Type 1 diabetes, Teplizumab, is now available through the NHS in England and Wales. This immunotherapy can grant individuals up to three additional years before the manifestation of symptoms necessitates lifelong insulin treatment.
The NHS medicines body has characterised this decision as "genuinely exciting," anticipating that hundreds of children and young people will benefit each year. Type 1 diabetes can emerge at any age, though diagnosis is most common in early adolescence.
Patient advocacy groups have described the drug's potential impact as "momentous," following decades of research and development. Karen Addington, Chief Executive of Breakthrough T1D, stated, "If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition. We now have a treatment that can help make that possible."
Type 1 diabetes occurs when the body's immune system mistakenly attacks and destroys the insulin-producing cells within the pancreas. This condition differs fundamentally from Type 2 diabetes, which is frequently, but not exclusively, linked to excess weight.
Individuals with Type 1 diabetes must diligently monitor their blood glucose levels and administer insulin, either via injections or an insulin pump, to compensate for the hormone their bodies can no longer produce adequately. Untreated, low blood sugar can constitute a medical emergency, whilst prolonged high levels can lead to damage to blood vessels and nerves.
Teplizumab must be administered as an infusion before symptoms develop, requiring a prior blood test to confirm the immune system has begun its attack on the pancreas. Whilst Italy operates a national screening programme for children and young people, routine testing for Type 1 diabetes is not yet available on the NHS in the UK, although diabetes charities are campaigning for its implementation.
Most individuals diagnosed with Type 1 diabetes lack a close family history of the condition, suggesting environmental factors may play a significant role in its initiation. Dima Boichak, from Newbury, discovered his high risk of developing the disease at age nine through a UK-wide research study. He subsequently became one of the first recipients of Teplizumab on compassionate grounds.
The National Institute for Health and Care Excellence (NICE) has recommended the drug, estimating that approximately 1,100 adults and children could be eligible in the first year, with around 820 per year in the longer term. Helen Knight, Director of Medicines Evaluation at NICE, remarked, "For the first time, we have a treatment that can give people diagnosed at an early stage precious extra time before they need to manage the full demands of the condition."
The published cost of Teplizumab is around £150,000 per course of treatment, though the NHS has secured a confidential discount from the manufacturer, Sanofi. Breakthrough T1D, which funded early research, noted that several other immunotherapy treatments for Type 1 diabetes are currently in development, with future aspirations for personalised drug combinations that might prevent insulin dependence entirely.
NICE guidance does not automatically extend to Northern Ireland, and in Scotland, the Scottish Medicines Consortium is expected to issue its advice on Teplizumab in early 2027.
